LLL12 is a small molecule inhibitor of STAT3 that inhibits STAT3 phosphorylation. LLL12 enhanced the inhibitory effect of Cisplatin (HY-17394) and Paclitaxel (HY-B0015) on ovarian cancer cell formation, migration, and growth[1].

LLO (190-201) (Listeriolysin O 190 peptide) is a biological active peptide. (This peptide is a major histocompatibility complex class II (MHC-II)-restricted peptide, LLO190 (NEKYAQAYPNVS), from the listeriolysin O protein of Listeria monocytogenes, which generates an LLO190-specific Th response. This peptide subsequently challenge recombinant L. monocytogenes expressing the MHC-I-restricted epitope of ovalbumin (Ova257, SIINFEKL).)

LM-41 is a Flufenamic acid-derived TEAD inhibitor hat strongly reduce the expression of CTGF, Cyr61, Axl and NF2. LM-41 inhibits migration of human MDA-MB-231 breast cancer cells[1].

LM-4108 (N-(2-Phenylethyl)-indomethacin amide) is a selective and orally active COX-2 inhibitor with an IC50 of 0.06 μM for purified human COX-2. LM-4108 shows anti-inflammatory activity and may be effective in prevention of cancer. Half-lives for the disappearance of 10 μM LM-4108 in rat, human, and mouse liver microsomes were 11 min, 21 min, and 51 […]

LM2I is a derivative of Spinosyn A (SPA). LM2I is argininosuccinate synthase (ASS1) enzyme activator, and tumor inhibitor that directly interact with ASS1. LM2I has significant antiproliferative activity in seven colorectal cancer cell-lines and xenograft tumors of colorectal cancer. LM2I inhibits colorectal cancer cell growth via the EGFR pathway[1].

LMP2A (426-434) is a biological active peptide. (HLA A2.1-restricted epitope from Epstein-Barr Virus latent membrane protein LMP2 (426-434).)

LMP517 (NSC 781517) a indenoisoquinoline, is a potent a dual TOP1 and TOP2 inhibitor. LMP517 shows better antitumor activity than its parent compound LMP744 (HY-U00248) against H82 (Small Cell Lung Cancer) xenografts. LMP517 induces TOP1 cleavage complexes (TOP1ccs) and TOP2ccs[1].

LMP7-IN-2 is a LMP7 inhibitor. LMP7-IN-2 can be used for associated inflammatory diseases and disorders[1].

LMTK3-IN-1 (compound C28) is an ATP-competitive inhibitor of lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM)，that acts by degrading LMTK3 via the ubiquitin-proteasome pathway. LMTK3-IN-1 shows anticancer activity in a variety of cancer cell lines and in vivo BC mouse models. LMTK3-IN-1 induces apoptosis in BC cell lines at 10-20 μM[1].

LMTK3-IN-1 (compound C28) is an ATP-competitive inhibitor of lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM)，that acts by degrading LMTK3 via the ubiquitin-proteasome pathway. LMTK3-IN-1 shows anticancer activity in a variety of cancer cell lines and in vivo BC mouse models. LMTK3-IN-1 induces apoptosis in BC cell lines at 10-20 μM[1].

LMW peptide is an antimicrobial peptide. LMW peptide is active against Gram-positive and Gram-negative bacterial, such as B. subtilis, L. monocytogenes, E. coli, P. aeruginosa, V. cholera[1].

LN5P45 is an OTUB2 inhibitor (IC50: 2.3 μM). LN5P45 induces monoubiquitination of OTUB2 on lysine 31. LN5P45 can be used for research of tumor progression and metastasis[1].

LNnDFH I is a natural product that can be isolated from human urine[1].

LNP Lipid-1 (Method B) is a lipid compound. LNP Lipid-1 is involved in the synthesis of lipid nanoparticles compositions. LNP Lipid-1 has potential applications in the transport of biologically active substances such as small molecule agents, proteins, and nucleic acids[1][2].

LNP Lipid-3 is an ionizable lipid extracted from patent WO2021113777A, and can be used for the generation of Lipid nanoparticles (LNPs).

LNP Lipid-4 (Compound 8-8) is a lipid compound. LNP Lipid-4 is involved in the synthesis of lipid nanoparticles compositions. LNP Lipid-4 has potential applications in the transportation of biologically active substances[1].

LNP Lipid-5 (Compound Lipid 2) is an ionizable lipid (amino lipid). LNP Lipid-5 can be used to prepare lipid nanoparticles (LNP)[1].

LNP Lipid-6 (Compound Lipid 5) is an ionizable lipid (amino lipid). LNP Lipid-6 can be used to prepare lipid nanoparticles (LNP)[1].

1LNP Lipid-7 (Compound 7013) is a lipid. LNP Lipid-6 can be used to prepare lipid nanoparticles (LNP) and for drug delivery[1].

1LNP Lipid-7 (Compound 7013) is a lipid. LNP Lipid-6 can be used to prepare lipid nanoparticles (LNP) and for drug delivery[1].

1LNP Lipid-7 (Compound 7013) is a lipid. LNP Lipid-6 can be used to prepare lipid nanoparticles (LNP) and for drug delivery[1].

1LNP Lipid-7 (Compound 7013) is a lipid. LNP Lipid-6 can be used to prepare lipid nanoparticles (LNP) and for drug delivery[1].

1LNP Lipid-7 (Compound 7013) is a lipid. LNP Lipid-6 can be used to prepare lipid nanoparticles (LNP) and for drug delivery[1].

LNP Lipid-8 (11-A-M) is an ionizable lipid, which can be used for lipid nanoparticles (LNP) to deliver siRNA to T cells without targeting to ligands. LNP LIPs-8 loaded with GFP siRNA (siGFP), and significantly causes GFP gene silencing in mice model[1].

LNP Lipid-8 (11-A-M) is an ionizable lipid, which can be used for lipid nanoparticles (LNP) to deliver siRNA to T cells without targeting to ligands. LNP LIPs-8 loaded with GFP siRNA (siGFP), and significantly causes GFP gene silencing in mice model[1].

LNP Lipid-8 (11-A-M) is an ionizable lipid, which can be used for lipid nanoparticles (LNP) to deliver siRNA to T cells without targeting to ligands. LNP LIPs-8 loaded with GFP siRNA (siGFP), and significantly causes GFP gene silencing in mice model[1].

LNP Lipid-8 (11-A-M) is an ionizable lipid, which can be used for lipid nanoparticles (LNP) to deliver siRNA to T cells without targeting to ligands. LNP LIPs-8 loaded with GFP siRNA (siGFP), and significantly causes GFP gene silencing in mice model[1].

LNP Lipid-8 (11-A-M) is an ionizable lipid, which can be used for lipid nanoparticles (LNP) to deliver siRNA to T cells without targeting to ligands. LNP LIPs-8 loaded with GFP siRNA (siGFP), and significantly causes GFP gene silencing in mice model[1].

Lobeglitazone is a new type of thiazolidinedione. Lobeglitazone can be used to prevent type 2 diabetes mellitus (T2DM)[1].

Lobeglitazone sulfate is a new type of thiazolidinedione. Lobeglitazone sulfate can be used to prevent type 2 diabetes mellitus (T2DM)[1].

Lobeline (α-Lobeline) is a brain-penetrant nicotinic receptor agonist. Lobeline increases dopamine (DA) release by inhibiting DA uptake into synaptic vesicles, and altering presynaptic DA storage. Lobeline is effective in smoking cessation[1][2].

Lobendazole is a potent anthelmintic. Lobendazole inhibits Giardia intestinalis strains[1].

Lobenzarit disodium (CCA) is an anti-arthritic and anti-oxidative agent[1].

Lobetyol is a natural compound that can be isolated from Lobelia chinensis. Lobetyol induces apoptosis and cell cycle arrest in MKN45 cells. Lobetyol shows anti-virus, anti-inflammation and anti-tumor activity[1][2]. Lobetyol is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Lochnerine is an indole alkaloid can be isolated from the stem bark extract of Alstonia macrophylla[1].

Locostatin (UIC-1005) is a potent RKIP inhibitor. Locostatin binds Raf kinase inhibitor RKIP protein and disrupts the interaction of RKIP with Raf-1 kinase and G protein-coupled receptor kinase 2. Locostatin inhibits cell proliferation and migration. Locostatin can be used to synthesize chemical probes toward PEBP-proteins. Locostatin aggravates thioacetamide (HY-Y0698)-induced acute liver failure in mice [1][2][3].

Locostatin (UIC-1005) is a potent RKIP inhibitor. Locostatin binds Raf kinase inhibitor RKIP protein and disrupts the interaction of RKIP with Raf-1 kinase and G protein-coupled receptor kinase 2. Locostatin inhibits cell proliferation and migration. Locostatin can be used to synthesize chemical probes toward PEBP-proteins. Locostatin aggravates thioacetamide (HY-Y0698)-induced acute liver failure in mice [1][2][3].

Locostatin (UIC-1005) is a potent RKIP inhibitor. Locostatin binds Raf kinase inhibitor RKIP protein and disrupts the interaction of RKIP with Raf-1 kinase and G protein-coupled receptor kinase 2. Locostatin inhibits cell proliferation and migration. Locostatin can be used to synthesize chemical probes toward PEBP-proteins. Locostatin aggravates thioacetamide (HY-Y0698)-induced acute liver failure in mice [1][2][3].

Locostatin (UIC-1005) is a potent RKIP inhibitor. Locostatin binds Raf kinase inhibitor RKIP protein and disrupts the interaction of RKIP with Raf-1 kinase and G protein-coupled receptor kinase 2. Locostatin inhibits cell proliferation and migration. Locostatin can be used to synthesize chemical probes toward PEBP-proteins. Locostatin aggravates thioacetamide (HY-Y0698)-induced acute liver failure in mice [1][2][3].

Locust bean gum is a natural polysaccharide derived from the seeds of the carob tree. It is commonly used as a thickening, stabilizing and gelling agent in a variety of foods, including dairy, baked goods and meat products. Locust bean gum has several properties suitable for these applications, including high water retention capacity, ability to […]

Lodapolimab (LY3300054) is an IgGλ anti-PD-1 monoclonal antibody[1].

LOE 908 hydrochloride is a non-selective cation channel (NSCC) inhibitor[1].

Lofepramine (Lopramine) hydrochloride is a potent tricyclic antidepressant and is extensively metabolised to Desipramine. The antidepressant activity of Lofepramine hydrochloride stems from the facilitation of noradrenergic neurotransmission by uptake inhibition. Lofepramine hydrochloride may also potentiate serotoninergic neurotransmission by inhibition of the neuronal uptake of serotonin and the enzyme tryptophan pyrrolase. Lofepramine hydrochloride has significant anxiolytic […]

Lomedeucitinib (BMS-986322) is act by targeting receptor tyrosine protein kinase (TYK2). Lomedeucitinib can be used for the research of plaque psoriasis[1].

Lometraline hydrochloride is an aminotetralin derivative and can be used for Parkinson’s disease research[1].

Lomtegovimab (BI 767551) is a humanized anti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19[1][2].

Lonazolac (hemicalcium) is the calcium salt form of Lonazolac. Lonazolac is a nonsteroidal antirheumatic agent with anti-inflammatory properties[1].

Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab shows antitumor activity and has potential application in non-Hodgkin’s lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL)[1][2].

Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab shows antitumor activity and has potential application in non-Hodgkin’s lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL)[1][2].

Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab shows antitumor activity and has potential application in non-Hodgkin’s lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL)[1][2].